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PD-L1 plays a central role in immune recognition of cancer cells. In this issue of Molecular Cell, Jin et al. (2019)
report that a phosphorylated retinoblastoma protein contacts the DNA-binding domain of p65 NF-kB,
thereby blocking transcription of PD-L1.
In this issue, Jin et al. (Jin et al., 2019) unveil a molecular mechanism in which the
retinoblastoma tumor suppressor protein
(RB) negatively regulates the NF-kB protein p65 to block expression of PD-L1
(Figure 1). The authors demonstrate that
cyclin-dependent kinase (CDK) 4 or 6 inhibitors can suppress PD-L1 expression
through this mechanism and offer an
experimental therapeutic approach to
counter radiation-induced tumor immune
evasion.
The RB tumor suppressor has long
been recognized to be negatively regulated by CDK phosphorylation. Growth
stimuli signal assembly of cyclin D and
CDK4/6, creating partially phosphorylated RB that releases E2Fs, which in
turn induce cyclin E expression. Cyclin
E-CDK2 complexes then hyperphosphorylate RB, fully relieving repression of E2Fs
and subsequent transcription of their
cell cycle target genes. Not surprisingly,
the CDK-RB-E2F regulatory pathway is
frequently inactivated in human cancers
by elevated CDK activity, and this deregulates cell proliferation (Rubin, 2013).
Based on these observations, phosphorylated RB has long been considered to be
inactive once a cell enters S phase, as
these modifications have been shown to
drastically alter its structure (Dick et al.,
2018). The present publication reveals
an intriguing mechanism in which CDK4
phosphorylation of RB enables an RBNF-kB interaction to inhibit transcription,
indicating that CDK phosphorylation of
RB can direct protein interactions and
not just disrupt them.

NF-kB p65 is one of five members of
this transcription factor family, and they
form homo- or heterodimers with each
other to bind DNA (Perkins, 2012). Dimers
are bound and negatively regulated by
members of the inhibitor of kB (IkB) protein family. Upon phosphorylation of IkB,
the inhibitor undergoes proteasomedependent degradation to allow the remaining NF-kB complex to enter the
nucleus and induce transcriptional expression of target genes that lead to
survival, proliferation, and other cellular
effects. To search for new cancer therapeutic strategies that exploit NF-kB, Jin
et al. (2019) used PC-3 prostate cancer
cells with shRNA gene-knockdown combinations designed to inactivate NF-kB
and create synthetic lethality. The authors
then searched for chemical agents that
could rescue lethality. In two shRNA combinations, treatment with a CDK4/6 inhibitor, palbociclib, rescued lethality, and this
was demonstrated both in cell culture and
in tumor xenografts. Prompted by this
drug screen, the authors then tested the
effect of RB loss on synthetic lethality
and found that RB knockdown similarly
improved cell viability and restored
expression of select NF-kB target genes,
implicating RB as a negative regulator of
NF-kB.
The authors elucidate a very detailed
and direct molecular explanation of RBmediated control of NF-kB transcription.
They demonstrated that RB specifically
binds and regulates the p65 subunit of
the NF-kB family. They show that the
N-terminal R-linker domain of RB inter-

acts with the N-terminal DNA-binding
domain of p65. The authors used unmodifiable mutant forms of RB to show
that phosphorylation at S249 and T252
mediate its interaction with p65 and that
maximal binding is dependent on cyclin
D-CDK4 phosphorylation. Furthermore,
Jin et al. (2019) present evidence that
phosphorylation of S249 and T252 reverses electrostatic repulsion between
positively charged residues in RB and
p65. Replacing positively charged arginine on p65 with aspartate bypasses the
need for phosphorylation of RB to induce
assembly. Endogenously, RB binding to
p65 inhibits DNA binding and prevents
NF-kB promoter occupancy and transcriptional activation. These experiments
establish the molecular determinants of
RB-p65 interactions and suggest that
other RB-binding proteins may be regulated by a similar mechanism in a phosphorylation-dependent manner (Gubern
et al., 2016).
The discovery of this molecular interaction between RB and p65 NF-kB provides
opportunities for future studies examining
the relationship between these two pathways. In this report, Jin et al. (2019)
focus on the implications of RB-NF-kB
regulation of PD-L1 expression because
of the therapeutic utility of PD-L1/PD-1
blockade in activating anti-tumor immunity (Sun et al., 2018). Ectopic expression
of an RB N-terminal fragment in PC-3
cells inhibits PD-L1 expression, whereas
a non-phosphorylatable mutant does not
inhibit PD-L1, further providing evidence
for the role of the upstream CDKs
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expression. Collectively, these studies
indicate that the effect of these drugs on
tumor growth and tumor immunity is
complex. This highlights the challenges
of predicting the outcome of various therapeutic tumor-immune system interactions that will need to be overcome in
order to use these agents to improve
anti-cancer immunity in the clinic.
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Figure 1. Phosphorylation of RB Stimulates Interaction with p65 NF-kB and Blocks
Transcription
In circumstances of p65 NF-kB activation and RB underphosphorylation (pictured at left), p65 activates
the PD-L1 promoter. RB is phosphorylated on S249 and T252 by CDK4, and this induces assembly of a
complex mediated by the RB N-linker and DNA-binding domain of p65. This inhibits DNA binding and
blocks PD-L1 expression (pictured at right). Treatment with CDK4/6 inhibitors such as palbociclib prevents RB phosphorylation and preserves active p65 NF-kB transcription of PD-L1.

mediating this effect. In addition, a short
S249D/T252D phospho-mimetic peptide,
but not its S249A/T252A version, inhibits
PD-L1 expression. This experiment was
reproducible not only in prostate cancer
cells, but also in pancreatic, lung, and
liver-derived cancer cell lines, suggesting
the RB-NF-kB regulatory interaction may
be applicable to various cancer types.
Since radiation can suppress immunity
in specific circumstances, and DNA damage signaling can lead to dephosphorylation of RB, radiation may stimulate PD-L1
expression. To investigate this, syngeneic
xenograft experiments were performed in
which tumor cells expressing the phospho-mimetic peptide or an empty vector
were irradiated and/or treated with antiPD-L1 to stimulate immune recognition.
The phospho-mimetic peptide synergized
with radiation treatment to inhibit tumor
growth compared to radiation or peptide
alone. Moreover, it was apparent that
the peptide has PD-L1-independent antitumor properties, as the radiation-peptide
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combination offered increased protection
against tumor growth versus radiation
and anti-PD-L1 combination treatment.
As proposed by the authors, there is an
intriguing yet largely unexplored role for
repressed p65-regulated pro-survival
genes such as Birc2 in mediating anti-tumor effects (Yang et al., 2016). Furthermore, the RB phospho-mimetic peptide
increased tumor T cell infiltration independent of PD-L1 blockade. These findings
strongly suggest that an in-depth interrogation of the CDK-RB-NF-kB regulated
transcriptome will reveal additional targets that mediate the anti-tumor response
in vivo.
Interestingly, a number of recent
studies using CDK4/6 inhibitors have reported upregulation of anti-tumor immunity instead of suppression (Goel et al.,
2017; Zhang et al., 2018). These studies
use different model systems to investigate immune recognition of tumors, and
CDK4/6 inhibitors are not exclusively
dependent on RB for effects on PD-L1
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